A Potent Human C5a Receptor Antagonist Protects against Disease Pathology in a Rat Model of Inflammatory Bowel Disease

Journal of Immunology

Volumn 171, Issue 10, 2003, Pages 5514-5520

  Woodruff, Trent M ^a   Arumugam, Thiruma V ^a   Shiels, Ian A ^a,b   Reid, Robert C ^a   Fairlie, David P ^a   Taylor, Stephen M ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Promics Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLPHENYL (ORNITHYLPROLYL DEXTRO CYCLOHEXYLALANYLTRYPTOPHYLARGININE); COMPLEMENT COMPONENT C5A RECEPTOR BLOCKING AGENT; INFLIXIMAB; MYELOPEROXIDASE; PREDNISOLONE; RECEPTOR BLOCKING AGENT; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; EDEMA; ENTERITIS; FOOD INTAKE; HISTOPATHOLOGY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; RECEPTOR BLOCKING; WEIGHT GAIN;

EID: 0242494255     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.10.5514     Document Type: Article

References (54)

1. van Deventer, S. J. H. 2002. Inflammatory bowel disease: future therapies. Curr. Treat. Options Gastroenterol. 5:207.
2. Nielsen, O. H., and J. Rask-Madsen. 1996. Mediators of inflammation in chronic inflammatory bowel disease. Scand J. Gastroenterol. Suppl. 216:149.
3. Kolios, G., C. Petoumenos, and A. Nakos. 1998. Mediators of inflammation: production and implication in inflammatory bowel disease. Hepato-Gastroenterology 45:1601.
4. Papadakis, K. A., and S. R. Targan. 2000. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 51:289.
5. Atreya, R., J. Mudter, S. Finotto, J. Mullberg, T. Jostock, S. Wirtz, M. Schutz, B. Bartsch, M. Holtmann, C. Becker, et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat. Med. 6:583.
6. Sandborn, W. J., and S. R. Targan. 2002. Biologic therapy of inflammatory bowel disease. Gastroenterology 122:1592.
7. Stack, W. A., S. D. Mann, A. J. Roy, P. Heath, M. Sopwith, J. Freeman, G. Holmes, R. Long, A. Forbes, and M. A. Kamm. 1997. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 349:521.
8. Rutgeerts, P., G. D'Haens, S. Targan, E. Vasiliauskas, S. B. Hanauer, D. H. Present, L. Mayer, R. A. van Hogezand, T. Braakman, K. L. DeWoody, et al. 1999. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117:761.
9. Sandborn, W. J., B. G. Feagan, S. B. Hanauer, D. H. Present, L. R. Sutherland, M. A. Kamm, D. C. Wolf, J. P. Baker, C. Hawkey, A. Archambault, et al. 2001. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120:1330.
10. Halstensen, T. S., and P. Brandtzaeg. 1991. Local complement activation in inflammatory bowel disease. Immunol. Res. 10:485.
11. Vogt, W. 1986. Anaphylatoxins: possible roles in disease. Complement 3:177.
12. Kirschfink, M. 1997. Controlling the complement system in inflammation. Immunopharmacology 38:51.
13. Henson, P. 2000. Complementing asthma. Nat. Immunol. 1:190.
14. Elmgreen, J. 1986. Complement and function of neutrophils in chronic inflammatory bowel disease. Dan. Med. Bull. 33:222.
15. Halstensen, T. S., T. E. Mollnes, P. Garred, O. Fausa, and P. Brandtzaeg. 1990. Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology 98:1264.
16. Halstensen, T. S., T. E. Mollnes, P. Garred, O. Fausa, and P. Brandtzaeg. 1992. Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. Gut 33:902.
17. Ueki, T., M. Mizuno, T. Uesu, T. Kiso, J. Nasu, T. Inaba, Y. Kihara, Y. Matsuoka, H. Okada, T. Fujita, and T. Tsuji. 1996. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC). Clin. Exp. Immunol. 104:286.
18. Kitano, A., T. Matsumoto, S. Nakamura, A. Obata, N. Oshitani, K. Okawa, and K. Kobayashi. 1992. New treatment of ulcerative colitis with K-76. Dis. Colon Rectum 35:560.
19. Kitano, A., T. Matsumoto, S. Nakamura, N. Oshitani, A. Obata, K. Okawa, Y. Inoue, K. Kobayashi, and H. Nakura. 1993. Multifunctional effects of anticomplementary agent K-76 on carrageenan-induced colitis in the rabbit. Clin. Exp. Immunol. 94:348.
20. Wong, A. K., A. M. Finch, G. K. Pierens, D. J. Craik, S. M. Taylor, and D. P. Fairlie. 1998. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a. J. Med. Chem. 41:3417.
21. Finch, A. M., A. K. Wong, N. J. Paczkowski, S. K. Wadi, D. J. Craik, D. P. Fairlie, and S. M. Taylor. 1999. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 42:1965.
22. Haynes, D. R., D. G. Harkin, L. P. Bignold, M. J. Hutchens, S. M. Taylor, and D. P. Fairlie. 2000. Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist. Biochem. Pharmacol. 60:729.
23. Mollnes, T. E., O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegard, J. Kohl, and J. D. Lambris. 2002. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100:1869.
24. Strachan, A. J., T. M. Woodruff, G. Haaima, D. P. Fairlie, and S. M. Taylor. 2000. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J. Immunol. 164:6560.
25. Strachan, A. J., I. A. Shiels, R. C. Reid, D. P. Fairlie, and S. M. Taylor. 2001. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist. Br. J. Pharmacol. 134:1778.
26. Arumugam, T. V., I. A. Shiels, T. M. Woodruff, R. C. Reid, D. P. Fairlie, and S. M. Taylor. 2002. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J. Surg. Res. 103:260.
27. Arumugam, T. V., I. A. Shiels, A. J. Strachan, G. Abbenante, D. P. Fairlie, and S. M. Taylor. 2003. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int. 63:134.
28. Woodruff, T. M., A. J. Strachan, N. Dryburgh, I. A. Shiels, R. C. Reid, D. P. Fairlie, and S. M. Taylor. 2002. Anti-arthritic activity of an orally active C5a receptor antagonist against antigen-induced monoarticular arthritis in the rat. Arthritis Rheum. 46:2476.
29. Neurath, M., I. Fuss, and W. Strober. 2000. TNBS-colitis. Int. Rev. Immunol. 19:51.
30. Bobin-Dubigeon, C., X. Collin, N. Grimaud, J. M. Robert, G. Le Baut, and J. Y. Petit. 2001. Effects of tumour necrosis factor-α synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis. Eur. J. Pharmacol. 431:103.
31. Rachmilewitz, D., P. L. Simon, L. W. Schwartz, D. E. Griswold, J. D. Fondacaro, and M. A. Wasserman. 1989. Inflammatory mediators of experimental colitis in rats. Gastroenterology 97:326.
32. Kim, H. S., and A. Berstad. 1992. Experimental colitis in animal models. Scand. J. Gastroenterol. 27:529.
33. Faubion, W. A., Jr., E. V. Loftus, Jr., W. S. Harmsen, A. R. Zinsmeister, and W. J. Sandborn. 2001. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121:255.
34. Jani, N., and M. D. Regueiro. 2002. Medical therapy for ulcerative colitis. Gastroenterol. Clin. North Am. 31:147.
35. van der Velden, V. H. 1998. Glucocorticoids: mechanisms of action and antiinflammatory potential in asthma. Mediat. Inflamm. 7:229.
36. Buchman, A. L. 2000. Side effects of corticosteroid therapy. J. Clin. Gastroenterol. 33:289.
37. Rutgeerts, P. J. 2001. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment. Pharmacol. Ther. 15:1515.
38. Fiorucci, S., E. Antonelli, E. Distrutti, P. Del Soldato, R. J. Flower, M. J. Clark, A. Morelli, M. Perretti, and L. J. Ignarro. 2002. NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc. Natl. Acad. Sci. USA 99:15770.
39. Kim, Y. S., M. Son, J. I. Ko, H. Cho, M. Yoo, W. B. Kim, I. S. Song, and C. Y. Kim. 1999. Effect of DA-6034, a derivative of flavonoid, on experimental animal models of inflammatory bowel disease. Arch. Pharm. Res. 22:354.
40. Yano, H., F. Hirayama, H. Arima, and K. Uekama. 2001. Prednisolone-appended α-cyclodextrin: alleviation of systemic adverse effect of prednisolone after intracolonic administration in 2,4,6-trinitrobenzenesulfonic acid-induced colitis rats. J. Pharm. Sci. 90:2103.
41. Mauras, N. 2001. Growth hormone therapy in the glucocorticosteroid-dependent child: metabolic and linear growth effects. Horm. Res. 1:13.
42. Grofte, T., D. S. Jensen, J. Greisen, N. Tygstrup, and H. Vilstrup. 2001. Growth hormone and insulin-like growth factor-I counteracts established steroid catabolism in rats by effects on hepatic amino-N degradation. J. Hepatol. 35:700.
43. Anstead, G. M. 1998. Steroids, retinoids, and wound healing. Adv. Wound Care 11:277.
44. Sandborn, W. J. 2001. Strategies targeting tumor necrosis factor in Crohn's disease. Acta Gastroenterol. Belg. 64:170.
45. Muller, T. 2002. CPI-1189: Centaur. Curr. Opin. Investig. Drugs 3:1763.
46. Kam, L. Y., and S. R. Targan. 2000. TNF-α antagonists for the treatment of Crohn's disease. Expert Opin. Pharmacother. 1:615.
47. Sands, B. E., W. J. Tremaine, W. J. Sandborn, P. J. Rutgeerts, S. B. Hanauer, L. Mayer, S. R. Targan, and D. K. Podolsky. 2001. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis. 7:83.
48. Valle, E., M. Gross, and S. J. Bickston. 2001. Infliximab. Expert Opin. Pharmacother. 2:1015.
49. Bitter-Suermann, D. 1988. The anaphylatoxins. In The Complement System. Springer-Verlag, Berlin, p. 367.
50. Wetsel, R. A., J. Kildsgaard, and D. L. Haviland. 2000. Complement anaphylatoxins (C3a, C4a, C5a) and their receptors (C3aR, C5aR/CD88) as therapeutic targets in inflammation. In Therapeutic Interventions in the Complement System. J. D. Lambris and V. M. Holers, eds. Humana Press, Totowa, p. 113.
51. Asghar, S. S., and M. C. Pasch. 2000. Therapeutic inhibition of the complement system. Y2K update. Front. Biosci. 5:E63.
52. Woodruff, T. M., A. J. Strachan, S. D. Sanderson, P. N. Monk, A. K. Wong, D. P. Fairlie, and S. M. Taylor. 2001. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation 25:171.
53. Regal, J. F., and D. G. Fraser. 1990. Recombinant human C5a-induced bronchoconstriction in the guinea-pig: a histamine independent mechanism. Pulm. Pharmacol. 3:79.
54. Short, A., A. K. Wong, A. M. Finch, G. Haaima, I. A. Shiels, D. P. Fairlie, and S. M. Taylor. 1999. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br. J. Pharmacol. 126:551.